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Abstract  23 
Lysosomal acid lipase (LAL) hydrolyzes cholesterol esters and triglycerides to free cholesterol 24 
and fatty acids,that are then used for the metabolic purposes in the cell. The process also 25 
occurs in immune cells which adapt their metabolic machinery to cope with the different 26 
energetic requirements associated to cell activation, proliferation and/or polarization. 27 
Deficiency of LAL not only causes severe lipid accumulation, but also impacts the 28 
immunometabolic signature in animal models. In humans, LAL deficiency has been recently 29 
associated with a peculiar clinical immune phenotype, secondary hemophagocytic 30 
lymphohistiocytosis. These observations indicate that LAL represents a critical player for 31 
cellular immunometabolic modulation and the availability of an effective enzyme replacement 32 
strategy makes LAL an attractive target to rewire the immunometabolic machinery of immune 33 
cells beyond its role in controlling cellular lipid metabolism.  34 
  35 
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The evolving concept of immunometabolism and the role of sterol metabolism in 36 
immune cells 37 
Dynamic changes in the metabolic machinery of immune cells occur during the 38 
activation, proliferation, mobilization and acquisition of effector or regulatory functions [1, 2]. 39 
The field of research which addresses these aspects is termed “immunometabolism” and 40 
specifically investigates the interplay among different metabolic pathways in supporting the 41 
anabolic versus the catabolic needs of immune cells under different conditions. While 42 
anabolic pathways provide the energy necessary for production of macromolecules, such as 43 
lipids and nucleotides, which mainly occurs in activated and proliferating cells, nutrient 44 
catabolism is directed toward the generation of energy during cell maintenance and it’s typical 45 
of quiescent, non-proliferating immune cells. Mitochondrial tricarboxylic acid (TCA) (see 46 
Glossary) cycle and oxidative phosphorylation (OXPHOS) from fatty acid oxidation (FAO) 47 
are thus maximized in resting conditions to generate ATP. Upon activation, the increased 48 
demand of energy and building blocks is fulfilled by the rapid increase of anaerobic glycolysis 49 
(a metabolic adaptation similar to the Warburg effect described for cancer cells [3]) as well 50 
as of aerobic catabolism of glucose and amino acids through OXPHOS. While in vitro the 51 
preference for glycolysis compared to OXPHOS clearly marks the functional state of 52 
activated immune cells, the picture is less clear in vivo. Indeed, while in in vitro experiments, 53 
glucose and glutamine concentrations, oxygen tension, cell density and the presence of 54 
growth factors and cytokines are strictly defined and controlled, they are extremely variable in 55 
vivo and may also differ among tissues of the body and be influenced by pathological 56 
conditions (i.e. cancer compared to healthy tissue). As example, while in vitro, regulatory T 57 
cells (Treg) engage both glycolysis and fatty acids oxidation (FAO) to support the energy 58 
demand, they are highly glycolytic when isolated from human blood [4, 5].  59 
Nutrients are an additional factor that can profoundly influence immune functions by 60 
shaping both cellular and systemic metabolism and therefore also play a key role in tuning 61 
physiological and pathological immune responses. Among the different nutrients, cholesterol 62 
is an essential component of mammalian cells, indispensable for survival and proliferation but 63 
cytotoxic when present as unesterified form at elevated intracellular levels [6]. Cholesterol is 64 
either synthesized through the mevalonate pathway or is acquired following the uptake of 65 
lipoproteins (where cholesterol is mainly present in the esterified form [7]). Low levels of 66 
intracellular cholesterol activate the sterol regulatory element binding proteins (SREBPs), 67 
4 
 
thus leading to transcriptional activation of genes required for cholesterol biosynthesis and 68 
uptake, such as HMGCoA reductase, the key enzyme of the mevalonate pathway and low 69 
density lipoprotein receptor (LDL-R), a key receptor involved in the uptake of lipoproteins [8]. 70 
Vice versa, when intracellular cholesterol is elevated, SREBP is retained in the endoplasmic 71 
reticulum (ER), the mevalonate pathway is inhibited, and oxidized metabolites of cholesterol, 72 
such as the oxysterols, activate the liver X receptors (LXRs), thus promoting the 73 
transcription of genes involved in cholesterol efflux, such as the ATP-binding cassette 74 
transporters ABCA1 and ABCG1 [9]. Of note, esterified cholesterol (CE), derived from 75 
lipoproteins or stored in lipid droplets (LD), can be hydrolyzed mainly within the lysosomal 76 
compartment by the action of the lysosomal acid lipase (LAL) [10]. This enzyme not only 77 
provides free cholesterol (FC) but also free fatty acids (FFA), and thus potentially contribute to 78 
the immunometabolic reprogramming of immune cells. The aim of this review is to discuss 79 
recent evidence linking LAL to cholesterol and fatty acids metabolism in the context of 80 
immunometabolism. 81 
 82 
Lysosomal acid lipase  83 
Expression and role of LAL in cell lipid metabolism 84 
LAL is a 378-amino acid protein which is expressed by all cell types and encoded by 85 
the LIPA gene on chromosome 10 (q23.2-q23.3) [11]. LAL is expressed constitutively [12] and 86 
its expression can be further increased following the activation of the transcription factor EB 87 
(TFEB), the master regulator of lysosomal biogenesis, and of the nutrient-sensitive forkhead 88 
homeobox type protein O1 (FoxO1) [13-15]. Newly synthetized LAL is transferred to the Golgi 89 
apparatus where it is glycosylated. The mannose-6-phosphate (M6P) residues allow the 90 
binding with the M6P receptor (M6PR) and the localization into the lysosome [16]. In the 91 
acidic environment of the lysosome, LAL dissociates from the M6P receptor and is 92 
dephosphorylated, thus generating the mature, active form of LAL. Its activity is rapidly 93 
reduced with the increase in pH, declining to zero at pH values above 4.5. 94 
The role of LAL is to hydrolyze CE and triglycerides (TG) that reach the lysosomes as 95 
the final step of the receptor-mediated endocytosis of very low- and low- density lipoproteins 96 
(VLDL, LDL) (Figure 1). The products of LAL hydrolysis are either actively exported by the 97 
Niemann-Pick type C protein (FC) or likely diffuse into the cytosol (FFA) [17, 18]. FC and FFA 98 
in the cytosol repress SREBPs [10, 19], thus reducing the expression of proteins involved in 99 
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cholesterol and fatty acid biosynthesis and uptake [8], and, when oxidized, favor LXR 100 
activation and ABCA1 expression in macrophages, thus increasing cellular cholesterol efflux 101 
[20, 21].  102 
LAL-derived FFA can be used for different purposes; in most cells FFA are directed 103 
toward the mitochondria where undergo oxidation and contribute to energy production; in 104 
addition, in hepatocytes FFA might be converted into TGs and incorporated in VLDL via MTP, 105 
while in adipocytes are released in the circulation or converted to TG and stored in LD 106 
(Figure 1). Moreover, while the mobilization of lipids from cytosolic LD to generate FFA has 107 
been originally attributed to neutral cytosolic or ER-associated lipases, several evidence 108 
highlighted the critical role of LAL in driving the hydrolysis of LD through the activation of 109 
autophagy/lipophagy [22], culminating with the formation of the autophagosome that 110 
eventually fuses with lysosomes [15, 23, 24] (Figure 1). The activation of lipophagy is 111 
sensitive to the nutritional status of the cell and it is now believed to play a key role in the 112 
metabolic switch related to cell differentiation process [25, 26]. 113 
When LAL is not active, CE and TG accumulate within the lysosomes; in the liver, this 114 
accumulation occurs in both hepatocytes and Kupffer cells (specialized macrophages in the 115 
liver) thus favoring hepatic steatosis. The decreased flux of FC and FFA to the cytosol 116 
activates SREBPs and represses LXRs. The net systemic effect on the hepatocyte is the 117 
increase of VLDL secretion [27] and the reduction of ABCA1-mediated cholesterol efflux 118 
coupled to the reduction of high density lipoproteins (HDL) biogenesis [28]. Both mechanisms 119 
contribute to the dyslipidemic profile observed in LAL defective conditions (see below).  120 
Given the 75% identity and 95% similarity in amino acid sequences of murine and 121 
human LAL [29], the use of lal-/- mice has provided a valuable approach to study the cellular 122 
processes regulated by the enzyme. Lal-/- mice present with a massive accumulation of TG 123 
and CE in the liver, the spleen, the small intestine and the adrenals, which is associated to 124 
the loss of white (WAT) and brown adipose tissues (BAT) [30]. Despite the appearance of 125 
hepatic foamy lysosomes, lal-/- mice show an improved insulin sensitivity and glucose 126 
metabolism [31], paralleled by a shift of lipid storage from hepatocytes to Kupffer cells over 127 
time [30]. This profile mirrors the observations in hepatic biopsies of LAL deficient patients 128 
(discussed below) [11]. Moreover, hematopoietic stem cell transplantation, although limited by 129 
graft failure and severity of pre-transplant liver disease, was successfully used in patients with 130 
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Wolman disease [32, 33] to restore LAL enzymatic activity in circulating cells and in resident 131 
macrophages, thus improving growth and survival rate.  132 
 133 
Role of LAL in immune cell maturation and function 134 
LAL plays a crucial role in controlling cholesterol levels in immune cells. Cholesterol 135 
accumulation, as a consequence of ABCA1, ABCG1 and apolipoprotein E (apoE) 136 
deficiency, results in monocytosis, macrophage activation, increased antigen presentation 137 
[34] and adaptive immune response [35-37]. In agreement, lal-/- mice accumulate cholesterol 138 
in the lysosome and develop a myeloproliferative disorder, characterized by increased 139 
frequency of both circulating and splenic immature monocytes and neutrophils (Figure 2a, 140 
Key Figure; a simplify immune system overview is provided in Box 1). This is paralleled by 141 
increased infiltration of myeloid-derived suppressive cells (MDSCs) in several organs. 142 
Anemia, thrombocytopenia and decreased lymphopoiesis were also detected in these mice 143 
[38, 39].  144 
LAL-dependent hydrolysis of CE in macrophages provides the substrate for the 145 
synthesis of 25-hydroxycholesterol and 27-hydroxycholesterol, both endogenous ligands of 146 
LXR, thus promoting cholesterol efflux and contributing to an efficient efferocytosis (a critical 147 
process for the phagocytosis of apoptotic cells) (Figure 2b) [40]. Further, the 148 
immunometabolic function of LAL also extends to the ability to contribute FFA following CE 149 
and TG hydrolysis, for energetic purposes. Indeed, in macrophages, LAL was shown to be 150 
critical in generating precursor molecules for the synthesis of lipid mediators such as 151 
eicosanoids (Figure 2b) [41]. Moreover, anti-inflammatory M2 macrophages rely on LAL-152 
dependent neutral lipid lipolysis to provide FFA which are used for FAO (Figure 2b) [26]. 153 
These fatty acids can be either synthesized within the cells and then packaged into LD or, 154 
collected from extracellular sources such as lipoproteins via CD36. Of note, only LAL, and no 155 
other lipases (i.e. adipose triglyceride lipase, ATGL, or the hormone-sensitive lipase, HSL), 156 
has been implicated in the hydrolysis of endogenous and exogenous TG for energy supply 157 
purposes in macrophages [26].  158 
In parallel with the impact on macrophage function, LAL has been shown to be crucial for the 159 
acquisition of the memory phenotype of CD8+ T cells (Figure 2c) contributing to the rapid 160 
hydrolysis and release for mitochondrial oxidation of fatty acids de novo synthesized. This 161 
process has been proposed to support a futile cycle where lipogenesis prompted from 162 
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glycolysis-derived acetyl-CoA contributes to the storage of neutral lipids in close proximity of 163 
ER and lysosome where they are later released as free fatty acids to support cell energy 164 
demand [25]. This metabolic adaptation, where both the anabolic and catabolic machineries 165 
are active, may reflect the trait of memory cells, long-living quiescent cells that should rapidly 166 
re-activate and proliferate upon re-exposure to the antigen. By contrast, effector T cells (Teff) 167 
mainly engage fatty acid uptake [42], as demonstrated by CD36 upregulation, which might 168 
fuel a faster activation [25]. In this scenario, adipose tissue derived-FFA might potentially 169 
represent an energetic fuel of immune cells [43]; indeed, compared to T memory cells at other 170 
sites, memory pathogen-specific T cells resident in the visceral adipose tissue (VAT) possess 171 
a higher proliferative capacity which is fulfilled by increased FA uptake and mitochondrial 172 
oxidation [44]. This mechanism has also been shown to be crucial for mitochondrial oxidation 173 
of VAT resident Tregulatory cells (Treg) [45], but not for Tregs in other tissues or under 174 
pathological microenvironment, including the tumors [46], where glycolysis-driven lipogenesis 175 
appears to fuel FAO. These evidences might indicate that immune cells would shape their 176 
metabolic machinery depending on local nutrients availability thus suggesting that LAL activity 177 
might contribute to immune cells’ activation. Indeed, it has been shown that obesity and lipid 178 
accumulation induce lysosome biogenesis in adipose tissue macrophages (ATM) [47] and 179 
that lysosomal-derived TG hydrolysis is essential for both adipose tissue homeostasis [48] 180 
and ATM function. Of note, deficiency of LAL associates with altered levels of Treg in 181 
lymphoid organs (Figure 2c) thus corroborating the crucial role of the enzyme in the 182 
maintenance of cell survival [39]. 183 
Collectively, LAL plays a key role in immune cell biology as it couples intracellular lipid 184 
metabolism to cell function. This suggests that the modulation of its activity may represent a 185 
valuable therapeutic option for the treatment of diseases characterized by dysregulated 186 
immune responses. Is this the case also in humans when LAL is not active? 187 
 188 
Genetics of LAL deficiency  189 
More than 50 different mutations in the LIPA gene affecting LAL expression or activity 190 
have been described in humans to date [11]. Mutations can span the entire gene and include 191 
point mutations and frameshifts [49]. Since two out of the three amino acid residues 192 
responsible for the enzymatic activity (Ser 153, Asp 324 and His 353) are located in the C-193 
terminal region of the protein, almost all nonsense mutations result in complete LAL 194 
8 
 
deficiency when present on both alleles [50].According to the residual enzymatic activity, 195 
genetic LAL deficiency (LAL-D, OMIM 278000) can present with a different spectrum of 196 
severity, from lethal Wolman Disease (WD) to less severe Cholesteryl Ester Storage Disease 197 
(CESD).  198 
WD, an extremely rare and recessive disease (1 case every 1,000,000 subjects), 199 
characterized by a neonatal onset which leads to death within the first year of life, is caused 200 
by near absence of LAL. Consequently, the massive accumulation of CE and TG in the liver, 201 
spleen, adrenal glands, bone marrow and lymph nodes cause hepatosplenomegaly, adrenal 202 
calcification, anemia and thrombocytopenia, respiratory failure, vomiting, diarrhea, cachexia 203 
and failure to thrive. Liver histology shows steatosis and fibrosis, rapidly progressing to 204 
cirrhosis. A recent analysis of 35 cases estimated a median age at death of 3.7 months and a 205 
0.26 probability of survival past 6 months of age [51]. 206 
Cholesteryl ester storage disease (CESD) is characterized by a residual LAL activity 207 
usually within 1-12% of the normal range. About 50-60% of CESD cases are carriers of a 208 
splicing variant in the last nucleotide of exon 8 (c.894G > A, p.Ser275_Gln298del) at least on 209 
one allele. The mutation (referred to as E8SJM) causes the skipping of exon 8, generating an 210 
inactive LAL; however, a small percentage of correct splicing (<5%) still assures a residual 211 
activity. The frequency of this mutation was used to estimate the overall prevalence of CESD 212 
in the general population which is 1:200 to 1:420 in heterozygosity, while the occurrence of 213 
homozygosity/compound heterozygosity ranges between 1:40.000 to 1:175.000 [49, 52, 53]. 214 
CESD presents with a wide range of severity, with onset from infancy to adulthood. Clinically, 215 
the accumulation of lipids mainly in the liver and in macrophages throughout the body results 216 
in hepatomegaly and splenomegaly; mortality is usually due to liver failure or cardiovascular 217 
disease. Liver histology shows a peculiar microvescicular steatosis that can rapidly evolve to 218 
fibrosis and micronodular cirrhosis [54, 55]. Biochemically, almost all CESD patients present 219 
with increased plasma levels of transaminases, especially alanine aminotransferase, and 220 
dyslipidemia: elevated plasma levels of total and LDL-cholesterol are associated with reduced 221 
HDL-cholesterol and less frequently to hypertriglyceridemia [54-56]. 222 
Despite the reports of occurrence of anemia, thrombocytosis, and the accumulation of 223 
lipids also in the bone marrow and the lymph nodes, few data are available on the impact of 224 
LAL-D on immune response in humans. Very recently, the presence of secondary 225 
hemophagocytic lymphohistiocytosis (HLH) was described in WD case reports [57-63]. 226 
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HLH is an immune disorder frequently associated with inborn errors of metabolism, including 227 
other lysosomal storage disorders. Since HLH phenotype is overlapping with several other 228 
conditions, the diagnosis is performed by the presence of at least 5 of the following 8 criteria: 229 
fever, splenomegaly, cytopenia, hypertriglyceridemia or hypofibrinogenemia, 230 
hyperferritinemia, reduced NK cell activity, elevated soluble CD25 and the presence of 231 
hemophagocytosis in the bone marrow (giant, lipid-laden histiocytes with cytoplasmic cellular 232 
fragments) . In one of the WD cases with secondary HLH, a 2-month-old Native American 233 
female homozygous for the c.658C>T (p.P220S) mutation in the LIPA gene, a further analysis 234 
of the immunophenotype was performed: a significant reduction in the absolute count of B 235 
lymphocytes, CD4+ and CD8+ T lymphocytes was detected, suggesting a potential 236 
impairment in humoral and cell-mediated adaptive immune response [63]. Although being 237 
limited to a small number of sporadic cases, these reports on such a rare disease as WD 238 
suggest that genetic LAL-D affects the immune phenotype also in humans and pave the road 239 
for further evaluations.  240 
 241 
LAL as a therapeutic target beyond genetic LAL-D  242 
LAL enzyme replacement therapy  243 
In spite of the dramatic phenotypes of LAL-D patients described above, until recently 244 
no therapeutic options were available for WD patients, while CESD patients were usually 245 
treated with lipid-lowering agents to control dyslipidemia (see Box 2). The therapeutic 246 
scenario completely changed in late 2015, when sebelipase alfa, a recombinant human LAL 247 
protein (rhLAL) produced in egg whites of transgenic hens, was approved as enzyme 248 
replacement therapy (ERT) for LAL-D by the Food and Drug Administration and the European 249 
Medicines Agency [64]. As with other enzymes for ERT of lysosomal disorders, sebelipase 250 
alfa is a glycoprotein carrying M6P moieties. Since the M6P receptors are expressed on the 251 
membrane of several cell types, including hepatocytes and macrophages, sebelipase alfa is 252 
taken up by all these cells and transported to the lysosomal compartment, where it can 253 
correct the phenotype resulting from the genetic LAL-D [56]. Sebelipase alfa can be life-254 
saving for WD, as suggested by the results of an open trial on 9 WD newborns: after an initial 255 
infusion of 0.35 mg/kg, sebelipase alfa dose was progressively increased up to 5 mg/kg once-256 
weekly [65]. Six of the patients treated with sebelipase alfa have survived to age ≥12 months 257 
and five to ≥24 months, with a marked improvement in growth parameters and liver function. 258 
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These data are in striking contrast to an estimated 26% probability to survive past 6 months of 259 
age when left untreated (see above).  260 
The efficacy of sebelipase alfa has been tested also in CESD patients. In the Acid 261 
Lipase Replacement Investigating Safety and Efficacy (ARISE) trial (ClinicalTrials.gov number 262 
NCT01757184), 66 patients were treated with 1.0 mg/kg of sebelipase alfa bi-weekly for 20 263 
weeks, followed by an extension period of up to 130 weeks [56]. After 20 weeks of treatment, 264 
sebelipase reduced LDL-cholesterol by 28.4% and TG by 25.5%, with a concomitant increase 265 
of HDL-cholesterol (+19.6%). The treatment also resulted in a significant improvement in liver 266 
function: plasma alanine aminotransferase levels were reduced by up to 60% and hepatic fat 267 
by 32%, leading to a decrease of steatosis in 62% of treated patients. To what extent the 268 
treatment with sebelipase alfa could alter cardiovascular and hepatic consequences of LAL-D 269 
in the long term is presently unknown. The extension period of the ARISE trial is aimed also 270 
at investigating the effect of sebelipase alfa on fibrosis. Preliminary data by Goodman et al 271 
showed a regression of fibrosis of >1-stage in 12 out of 20 patients, no change in fibrosis 272 
severity in 6 patients, while worsening was observed in 2 patients [66].  273 
 274 
Evidence for LAL replacement therapy on immune cell function 275 
To date there are no studies which address the effect of ERT on the immune system of LAL-D 276 
patients. However, in a case of WD with secondary hemophagocytic lymphohistiocytosis, the 277 
treatment with sebelipase for 3 months resulted in the normalization of lymphocytes B cells’ 278 
levels, while no changes were observed in the T cells’ levels [63]. Most of the current 279 
evidence of the impact of LAL restoration on immune cells function, come from studies 280 
performed in mice. Reconstitution of hLAL activity in myeloid cells of lal−/− mice, achieved 281 
through a doxycycline-inducible transgenic system, was shown to ameliorate myelopoiesis in 282 
the bone marrow and to reduce systemic expansion of MDSCs. Myeloid hLAL expression 283 
inhibited the production of reactive oxygen species (ROS) from neutrophils and their tissue 284 
infiltration [67]. The observation that in vitro rhLAL treatment of lal-/- macrophages increased 285 
the expression of ABCA1 transporter, thus enhancing excess cholesterol efflux from the cell 286 
[21], suggests that this effect might depend on an ameliorated handling of intracellular 287 
cholesterol in immune cells. In agreement to this hypothesis, foamy macrophages were 288 
shown to take up rhLAL in the atherosclerotic plaque of ldl-r-/- treated mice, decreasing the 289 
lesion size by 50% when compared to controls [68]. Of note, mice developed anti-rhLAL 290 
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antibodies which however did not appear to inhibit LAL activity [68]; whether this immune 291 
activation might have also affected the functionality of other immune cells in the experimental 292 
setting used has not been investigated. 293 
Taken together, these observations point to the potential role of immune cell-derived LAL in 294 
restoring intracellular cholesterol homeostasis, correcting aberrant immuno-inflammatory 295 
response thus paving the road for considering LAL as a novel immunometabolic target. 296 
 297 
Concluding remarks and future perspectives 298 
An intimate communication exists between cell metabolism and immune function. The 299 
regulation of cellular lipid homeostasis is achieved by several, highly controlled, steps. LAL 300 
represents a key protein controlling the availability of FC and FFA, the building and energy 301 
blocks of the cells. Thus, targeting lipid metabolism in immune cells may offer a therapeutic 302 
option not only for the treatment of metabolic disorders such as dyslipidemia, but also could 303 
potentially rewire the function of the immune system. Restoring LAL activity via ERT not only 304 
improves metabolic parameters in LAL-D patients, but is associated, at least in experimental 305 
models, with the improvement of the immuno-inflammatory responses, characterized by the 306 
decrease of myeloid cell proliferation and activation, as a consequence of increased 307 
cholesterol efflux (Figure 3a), by the production of pro-resolving lipid mediators and involved 308 
in efferocytosis (Figure 3b), and by the boost of Treg and CD8+T memory cells oxidative 309 
metabolism (Figure 3c). Since the cellular uptake of sebelipase alfa requires the expression 310 
of the M6P receptor, translating this approach for immune purposes will be more effective in 311 
those cells where M6P is elevated (See Outstanding Questions). Most of the circulating 312 
leukocytes express the M6PR and, moreover, its expression has been reported to be 313 
upregulated approximately 4-fold on blood monocytes incubated with lipopolysaccharide [69] 314 
and on activated T cells [70]. These observations, together with data showing how modulation 315 
of lipid metabolism impacts on immune activities, offer the rationale to target LAL with ERT as 316 
a novel option for the treatment of immunometabolic diseases. 317 
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 531 
 TEXT BOXES 532 
 533 
BOX 1. Immune system overview. 534 
The immune system comprises a series of tissues, cells and molecules that protect the body 535 
from not self material and is classically divided in the innate and the adaptive arms. 536 
Granulocytes, monocytes, macrophages represent the key components of the innate arm 537 
while antigen presenting cells, B and T cells belong to the adaptive arm. 538 
Immune cells originate from hematopoietic stem cell precursor (HSP), self-renewing stem 539 
cells that can differentiate into any blood cell type, located in perivascular bone marrow 540 
niches [71]. HSP differentiate in MPPs (multipotent progenitors), that subsequently originate 541 
the CLPs (common lymphoid progenitors) and CMPs (common myeloid progenitors) (Figure 542 
box 1). Whereas CLPs migrate to the thymus to complete the maturation to T cells, NK cells 543 
or B cells, CMPs further differentiate to GMP (granulocyte-macrophage progenitor) or MKEP 544 
(megakaryocyte-erythrocyte progenitor) (Figure box 1). While MKEPs originate 545 
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megakariocytes and erythrocytes, the GMPs differentiate to granulocytes or monocytes that 546 
are released in the circulation. Myeloproliferative disorders are characterized by the 547 
overproduction of one type of blood immune cells, such as leukemias, while anemia, identifies 548 
diseases associated to decreased blood cells production. Hemophagocytic 549 
lymphohistiocytosis (HLH) is an example of myeloproliferative diseases characterized by the 550 
production of excessive activated macrophages (known as histocytes) and lymphocytes. 551 
Patients with HLH usually develop fever, enlarged liver or spleen, cytopenia, and neurological 552 
abnormalities within the first months or years of life. HLH may be inherited in an autosomal 553 
recessive manner or can be acquired. Other abnormalities in hematopoiesis include the 554 
increase of myeloid-derived suppressor cells (MDSC) under pathological conditions, which 555 
might occur in chronic infections or cancer. MDSC, exert a strong immunosuppressive 556 
function thus leading to the inhibition of T cell proliferation and activation.  557 
The different subsets of immune cells are recognized on the basis of the expression of 558 
peculiar patterns of superficial receptors that account for their specific functions, (Figure box 559 
1). Broadly, all leucocytes express CD45, with circulating myeloid cells expressing the CD11b 560 
marker, B lymphocytes expressing CD19 and CD20 and T lymphocytes expressing CD3. 561 
CD11b+ myeloid cells are then divided in granulocytes (CD11b+/Gr-1+ in mice 562 
CD11b+/CD16+ in humans) and monocytes (CD11b+/Ly6C+ and CD11b+/CD14+ in 563 
humans), that further differentiate to macrophages (CD11b+/CD68 in humans and mice while 564 
F4/80+ only in mouse) once migrated into tissue. These cells represent the innate arm of 565 
immune response as they activate in an unspecific manner upon the encounter with any not-566 
self antigen by its phagocytosis, cytokine and ROS (reactive oxygen species) production. By 567 
contrast, cells of the adaptive immune response need to be “instructed” by professional 568 
antigen presenting cells (as dendritic cells, characterized by CD11c expression). Lymphocyte 569 
T cells (CD3+) are further divided in CD4+ (T helper) and CD8+ (T cytotoxic). After activation, 570 
a pool of CD4+ and CD8+ T cells persists as memory cells that can be rapidly re-activated 571 
following encounter with the same not-self antigen. Paralleled to the effector arm, the 572 
adaptive immune response comprises a tolerogenic response carried by regulatory T cells 573 
(Treg), a subset of CD4+ T cells that maintain tolerance to self-antigen thus preventing 574 
autoimmunity and patrolling for exaggerated immune activation. 575 
 576 
BOX 2. Management of CESD with lipid-lowering agents  577 
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Since CESD is characterized by hypercholesterolemia associated with low high density 578 
lipoprotein (HDL)-cholesterol and increased TG, lipid-lowering agents (mainly statins) are 579 
usually prescribed to the patients. Statins are reported to have a variable effect on total and 580 
LDL-cholesterol, with some patients responding well while others not. The average reduction 581 
for TC is around 20-30% [55]. The effect of statins on liver disease in CESD is still debated. 582 
Indeed, one would expect that the statin-mediated inhibition of cholesterol biosynthesis in the 583 
liver, which leads to the SREBP2-mediated upregulation of LDL-R expression, might 584 
contribute to an increase of hepatic uptake of LDL with a consequent worsening of hepatic 585 
steatosis. Consistently, statins were not associated with transaminases normalization in 586 
CESD patients [55]. 587 
Some reports indicate the use of ezetimibe in CESD patients, but robust data are not yet 588 
available on its lipid-lowering efficacy alone or in combination with statins [55, 72]. However, 589 
in lal-/- mice, ezetimibe significantly reduces the amount of CE sequestered in the liver and 590 
small intestine, thus improving liver steatosis and suggesting that intestinal cholesterol 591 
absorption could also play a role in cellular lipid accumulation observed in LAL-D [73]. In line 592 
with this, an amelioration of liver disease was observed in young CESD patients treated with 593 
ezetimibe alone or in association with statins [72, 74, 75]. 594 
 595 
 FIGURE LEGENDS 596 
 597 
Figure 1. Role of LAL in cell lipid metabolism 598 
Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and 599 
triglycerides (TG) carried by apoB-containing lipoproteins, as LDL and VLDL, which are 600 
internalized by receptor-mediated endocytosis. Generated free cholesterol (FC) and free fatty 601 
acids (FFA) are released into the cytosol, where their accumulation regulates their own 602 
synthesis and metabolism through the interaction with different transcription factors. The 603 
activation of autophagy also leads to the transport of lipid droplets (LD) to the lysosomes for 604 
the LAL-mediated hydrolysis and generation of FFA. This pathway is alternative to the 605 
classical mobilization of LD-stored FFA by neutral hydrolases. FFA could have different 606 
metabolic fates according to the cell type and the nutritional state. Cytosolic FFA can enter 607 
the fatty acid oxidation cascade for ATP production. In adipocytes, FFA are released in the 608 
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circulation or are converted to TG. In hepatocytes, TG are packed by MTP into VLDL and 609 
secreted. 610 
Abbreviation used: ABC, ATP-binding cassette; CE, cholesteryl esters; FAO, fatty acid 611 
oxidation; FC, free cholesterol; FFA, free fatty acids; LD, lipid droplets; LDL, low density 612 
lipoproteins; LDL-r, LDL-receptor; LXRs, liver X receptors; MTP, microsomal transfer protein; 613 
SREBPs, sterol-regulatory element binding proteins; TG, triglycerides. 614 
 615 
Figure 2, Key Figure. Consequences of LAL deficiency in immune cells 616 
LAL deficiency (LAL-D) (a) promotes excessive proliferation of myeloid cells and impaired 617 
maturation of monocytes and neutrophils leading to increased circulating levels of MDSC 618 
(myeloid-derived suppressor cells), (b) impairs macrophage polarization toward M2, 619 
efferocytosis and eicosanoids production, (c) decreases lymphopoiesis, the frequency of 620 
CD8+ T cells memory cells and of Tregulatory (Treg) cells in lymphoid organs.   621 
 622 
Figure 3. Potential effects of LAL replacement therapy on immune functions 623 
Recombinant LAL is delivered to the lysosomes via the mannose 6-phosphate receptor 624 
(M6PR). Enhanced LAL activity increases the flux into the cytosol of free cholesterol (FC), 625 
triggering the activation of the LXR pathway, while free fatty acids (FFA) fuel mitochondrial 626 
FAO. (a) In macrophages, this results in increased cholesterol efflux, a mechanism that has 627 
been shown to dampen excessive myeloid proliferation and dyslipidemia. (b) In addition, LAL-628 
dependent activation of the LXR pathway might improve efferrocytosis and promote 629 
macrophage polarization toward anti-inflammatory M2 phenotype. All these mechanisms 630 
could protect toward atherosclerosis development. (c) Fueling FAO in CD8+ memory T cells 631 
and T regulatory cell would represent a potential approach to modulate adaptive immune 632 
responses in the context of auto-immune disorders and cancer.  633 
 634 
  635 
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 Glossary 636 
 637 
Antigen presentation: A process consisting in foreign antigen fragmentation and processing 638 
by phagocytes, usually macrophages and dendritic cells, followed by the binding of peptides 639 
to the major histocompatibility complex (MHC), and transport to the surface of the cell, where 640 
it can be recognized by the T cell receptor or the B cell receptor. 641 
Apolipoprotein E (apoE): An apolipoprotein that plays a key role in cholesterol transport 642 
throughout the body. Liver-derived apoE associate to lipoproteins and promotes the 643 
catabolism of very-low density lipoprotein (VLDL) and low density lipoprotein (LDL); myeloid 644 
cell’ derived apoE is involved in cholesterol efflux from the cells.  645 
ATP-binding cassette transporters A1 and G1 (ABCA1, ABCG1): Transmembrane ATP-646 
dependent lipid transporters which promote the efflux of cellular cholesterol and phospholipids 647 
to extracellular acceptors, as high-density lipoproteins (HDL), apolipoprotein A-I or 648 
apolipoprotein E. 649 
Autophagy: A regulated process used by the cell for degradation and recycling of 650 
unnecessary or altered cellular components. It usually consists in the formation of double-651 
membraned vesicle, the autophagosome, that fuses with lysosomes. Three forms of 652 
autophagy commonly exist: macroautophagy, microautophagy, and chaperone-mediated 653 
autophagy. 654 
Cluster of differentiation 36 (CD36): A glycosylated transmembrane protein which belongs 655 
to the class B scavenger receptor family. It is expressed on the surface of several cell types 656 
and it is a multifunctional receptor, since it recognizes modified phospholipids, fatty acids and 657 
proteins containing thrombospondin-homolog domains. Oxidized LDL, which carry negatively 658 
charged phospholipids, are also recognized and internalized by CD36. 659 
Glycolysis: A sequence of enzyme-catalyzed reactions that converts glucose into pyruvate. 660 
Hemophagocytic lymphohistiocytosis (HLH): A rare but potentially fatal disease where 661 
phenotypically normal histiocytes and lymphocytes are overactive. This disease commonly 662 
appears in infancy and can have a genetic base or be secondary to other conditions such as 663 
LAL deficiency. 664 
Fatty acid oxidation (FAO): The catabolic process by which fatty acids are broken down to 665 
generate acetyl-CoA. 666 
22 
 
Futile cycle: A process that occurs when two metabolic pathways run simultaneously in 667 
opposite directions and have no overall effect other than to dissipate energy in the form of 668 
heat. In the context of immune cells, this term has been used to indicate the concomitant 669 
presence of the anabolic and catabolic pathways. 670 
Hepatic steatosis: A pathological condition characterized by excess lipid accumulation in the 671 
liver. Two types of steatosis are reported: the alcoholic liver disease and non-alcoholic fatty 672 
liver disease (NAFLD), which usually develops as a complication of diabetes and obesity. 673 
Lipid droplets (LD): Cytosolic bodies that act as intracellular stores of fatty acids and 674 
cholesterol in the form of neutral lipids. These are directly hydrolyzed in the cytosol by neutral 675 
lipases or are routed to the lysosomes by autophagy to meet energy requirements in the cell. 676 
Lipoproteins: Complex particles made of a central core of esterified cholesterol and 677 
triglycerides surrounded by free cholesterol, phospholipids and apolipoproteins. They allow 678 
the transport of water-insoluble lipids and are classified according to their density and 679 
composition into: chylomicrons, very-low density lipoproteins (VLDL), intermediate density 680 
lipoproteins (IDL), low density lipoproteins (LDL), high density lipoproteins (HDL) and 681 
lipoprotein (a) (Lp(a)). VLDL and LDL contain apolipoprotein B as the main protein component 682 
and their role is to deliver lipids from the liver to peripheral tissues. On the contrary, HDL, 683 
whose main protein component is apolipoprotein A-I, are the vehicles for the so-called 684 
reverse transport of cholesterol from peripheral tissues to the liver. 685 
Liver X receptor (LXR): Nuclear receptor family of transcription factors that are important 686 
regulators of cholesterol, fatty acid, and glucose homeostasis. Two isoforms of LXR have 687 
been identified: LXRα and LXRβ. While LXRβ is ubiquitously expressed, LXRα is expressed 688 
mainly in the liver, but is also found in the kidney, intestine, fat tissue, macrophages, lung, 689 
and spleen. LXRα and LXRβ form heterodimers with the 9-cis retinoic acid receptor (RXR), 690 
following the presence of an LXR agonist (such as oxysterols). LXR controls the transcription 691 
of genes that regulate lipids and cholesterol metabolism thus pinpoint their crucial role in cell 692 
metabolism and metabolic diseases. 693 
Lymphopoiesis: The generation of lymphocytes from a hematopoietic cell precursor. B cell 694 
lymphopoiesis is completed in the bone marrow, whereas T cell lymphopoiesis occurs in the 695 
thymus. 696 
Lysosomal acid lipase (LAL): Enzyme responsible for the hydrolysis of cholesteryl esters 697 
and triglycerides in the lysosomes. 698 
23 
 
Mannose-6-phosphate receptor (M6PR): Member of the P-type lectin family involved in the 699 
transport of acid hydrolases from the Golgi to the lysosomes. In the Golgi apparatus, acid 700 
hydrolases are modified with the addition of mannose-6-phoshate (M6P) residues, which 701 
allow their recognition by the M6PR on the surface of lysosomes. M6PR is also expressed on 702 
the surface of several cell types, favoring the cellular uptake of proteins carrying M6P 703 
residues. 704 
Myelopoiesis: The process of blood cells development from a myeloid progenitor cell. 705 
Myeloid-derived suppressor cells (MDSCs): A heterogeneous population of cells defined 706 
by their myeloid origin, immature state and ability to potently suppress T cell responses. 707 
Oxidative phosphorylation (OXPHOS): The metabolic process by which ATP is generated 708 
as the result of the transfer of electrons by a series of electron transport proteins in the 709 
mitochondria. 710 
Sterol element-binding proteins (SREBPs): A family of transcription factors belonging to 711 
the basic-helix-loop-helix leucine zipper class and consisting of two genes, the SREBF1 and 712 
SREBF2, that encode for three different proteins: SREBP1a, SREBP1c and SREBP2. SREB 713 
proteins regulate the transcription of genes involved in cholesterol biosynthesis and uptake, 714 
and fatty acid biosynthesis. 715 
T lymphocytes: A subset of white blood cell that play a central role in adaptive immunity. 716 
They can be differentiated into CD4+ helper T cells that contribute immune response by 717 
secretion of cytokines, CD4+ regulatory T cells that maintain immunological tolerance, and 718 
CD8+ cytotoxic T cells that kill virus-infected and tumor cells and are also implicated in 719 
transplant rejection. 720 
Transaminases: Hepatic enzymes that catalyze a transamination reaction between an amino 721 
acid and an α-keto acid required for amino acid synthesis. Increased transaminanses plasma 722 
levels mark liver or cardiac damage. 723 
Tricarboxylic acid cycle (TCA): A series of chemical reactions used to generate adenosine 724 
triphosphate (ATP) via the oxidation of acetyl-CoA derived from carbohydrates, fats, and 725 
proteins. 726 
Warburg Effect: A phenomenon characterized by increased rate of glucose uptake in which 727 
cells produce energy through increased aerobic glycolysis and preferential production of 728 
lactate, even in the presence of oxygen. 729 
